Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- Generic Name
- Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen
- Brand Names
- Pedvaxhib, Vaxelis
- Drug Type
- Biotech
- Unique Ingredient Identifier
- LUY6P8763W
- Background
Haemophilus influenzae type b capsular polysaccharide meningococcal outer membrane protein conjugate antigen is a vaccine containing outer membrane antigen extracted from Haemophilus influenzae.
- Associated Conditions
- Invasive Infection caused by Haemophilus Influenzae Type B
Immunogenicity of H. Influenzae Type b PRP-OMP Vaccines in American Indian and Alaska Native Children (the HibVax Study)
Phase 4
Completed
- Conditions
- Haemophilus Influenzae Type B Infection
- Interventions
- First Posted Date
- 2021-07-27
- Last Posted Date
- 2024-06-24
- Lead Sponsor
- Johns Hopkins Bloomberg School of Public Health
- Target Recruit Count
- 333
- Registration Number
- NCT04978818
- Locations
- 🇺🇸
Shiprock Center for Indigenous Health, Shiprock, New Mexico, United States
🇺🇸Gallup Center for Indigenous Health, Gallup, New Mexico, United States
🇺🇸Fort Defiance Center for Indigenous Health, Fort Defiance, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath